Skip to main content

Table 3 Results of in vitro testing for drug-resistance for children TBM in Southwest China, 2013–2018 (n = 42)

From: Epidemiological, clinical characteristics and drug resistance situation of culture-confirmed children TBM in southwest of China: a 6-year retrospective study

Individual drugNo.(%) of isolates with resistant to (n = 42)
Any drug resistancea13 (31.0)
Any first-line drug resistance12 (28.6)
Any second-line drug resistance3 (7.1)
STR4 (9.5)
INH10 (23.8)
RIF3 (7.1)
EMB0 (0.0)
OFX1 (2.4)
LFX0 (0.0)
AMK1 (2.4)
CM0 (0.0)
PTO1(2.4)
MFX1 (2.4)
RFB1 (2.4)
MDR (INH + RIF)2 (4.8)
pre-XDR0 (0.0)
XDR1 (2.4)
INH + STR2 (4.8)
INH + RIF + STR1 (2.4)
INH + RIF + EMB0 (0.0)
RIF + STR + EMB0 (0.0)
INH + RIF + STR + EMB0 (0.0)
  1. TBM tuberculosis meningitis, DST drug sensitivity testing, INH isoniazid, STR streptomycin, RIF rifampicin, EMB ethambutol, OFX Ofloxacin, LFX Levofloxacin, MFX Moxifloxacin, PTO Protionamid, RFB Rifabutin, AMK Amikacin, CM Capreomycin, MDR-TB multidrug-resistant tuberculosis, XDR extensively drug-resistant tuberculosis; a: Resistant to at least one drug